PacBio reports smaller-than-expected loss in Q2

Pacific Biosciences of California

07/08/2025 22:03

Overview

PacBio Q2 revenue rises to $39.8 mln from $36.0 mln yr/yr

Adjusted net loss per share of $0.13 beats analyst expectations, per LSEG data

Adjusted net income of -$40 mln beats estimates, per LSEG data

Result Drivers

HIFI SEQUENCING ADOPTION - Increased adoption of HiFi sequencing platforms, particularly Revio and Vega systems, contributed to revenue growth

CHINA EXPANSION - New distribution agreement in China expanded access to clinical lab networks, supporting revenue in clinical and research settings

COST MANAGEMENT - Reduced operating expenses helped lower net loss

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Adjusted EPS
Beat
-$0.13
-$0.17 (8 Analysts)
Q2 EPS
-$0.14
Q2 Adjusted Net Income
Beat
-$40 mln
-$51.50 mln (7 Analysts)
Q2 Adjusted Gross Profit
$15.20 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 8 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Pacific Biosciences of California Inc is $1.80, about 23.3% above its August 6 closing price of $1.38

Press Release: ID:nGNX7D1dNk

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)